Felice Strollo
Overview
Explore the profile of Felice Strollo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan K, Manoli A, Shojaee-Moradie F, Hutchison E, Strollo F, Koehler G, et al.
Diabet Med
. 2024 Nov;
42(3):e15472.
PMID: 39521725
No abstract available.
2.
Strollo F, Guarino G, Satta E, Gentile S
Diabetes Ther
. 2024 Jul;
15(9):1855-1860.
PMID: 39085745
Tirzepatide is the first ever once-weekly, injectable gastric inhibitory peptide/glucagon-like peptide 1 (GIP/GLP-1) dual agonist approved by the European Medicines Agency for type 2 diabetes. The efficacy and safety of...
3.
Guarino G, Strollo F, Della Corte T, Satta E, Gentile S
Diabetes Ther
. 2024 Apr;
15(6):1485-1490.
PMID: 38649533
No abstract available.
4.
Gentile S, Strollo F
Diabetes Res Clin Pract
. 2024 Mar;
209:111600.
PMID: 38428747
No abstract available.
5.
Cialdai F, Brown A, Baumann C, Angeloni D, Baatout S, Benchoua A, et al.
NPJ Microgravity
. 2023 Oct;
9(1):84.
PMID: 37865644
The present white paper concerns the indications and recommendations of the SciSpacE Science Community to make progress in filling the gaps of knowledge that prevent us from answering the question:...
6.
Monda V, Voci C, Strollo F, Passaro A, Greco S, Monesi M, et al.
Diabetes Ther
. 2023 Oct;
14(12):2127-2142.
PMID: 37801224
Introduction: Type 2 diabetes mellitus (T2DM) is a relevant risk factor for severe forms of COVID-19 (SARS coronavrus 2 [SARS-CoV-2] disease 2019), and calls for caution because of the high...
7.
Guarino G, Strollo F, Della Corte T, Satta E, Gentile S
Diabetes Ther
. 2023 Oct;
14(12):2089-2108.
PMID: 37789214
Introduction: Non-alcoholic fatty liver disease (NAFLD) is part of a disease spectrum ranging from steatosis to steatohepatitis (NASH), fibrosis, and cirrhosis, and when associated with metabolic syndrome (MS), and overt...
8.
Cigrovski Berkovic M, Strollo F
World J Diabetes
. 2023 May;
14(4):424-434.
PMID: 37122431
Semaglutide is a glucagon-like peptide-1 receptor agonist used either orally every day or subcutaneously once a week for the treatment of type 2 diabetes mellitus and, more recently, at higher...
9.
Gentile S, Guarino G, Della Corte T, Marino G, Satta E, Pasquarella M, et al.
Diabetes Ther
. 2022 Dec;
14(1):179-191.
PMID: 36472805
Introduction: Cutaneous lipohypertrophy (LH) is a thickened, "rubbery" lesion in the subcutaneous tissue following multiple injections performed at the same site, i.e., an incorrect injection technique. It is widespread, averaging...
10.
Monda V, Gentile S, Porcellati F, Satta E, Fucili A, Monesi M, et al.
Adv Ther
. 2022 Sep;
39(11):4837-4846.
PMID: 36112311
After examining the complex interplay between heart failure (HF) in its various clinical forms, metabolic disorders like nonalcoholic fatty liver disease (NAFLD), and obstructive sleep apnea (OSA) syndrome, in this...